Mizuho Markets Americas LLC Purchases New Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Mizuho Markets Americas LLC acquired a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the third quarter, HoldingsChannel reports. The institutional investor acquired 195,613 shares of the specialty pharmaceutical company’s stock, valued at approximately $11,670,000.

Several other large investors have also modified their holdings of the stock. Millennium Management LLC lifted its position in ANI Pharmaceuticals by 1,005.8% in the second quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock valued at $14,651,000 after acquiring an additional 209,272 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of ANI Pharmaceuticals by 149.7% during the third quarter. Assenagon Asset Management S.A. now owns 186,179 shares of the specialty pharmaceutical company’s stock worth $11,107,000 after purchasing an additional 111,613 shares in the last quarter. F M Investments LLC purchased a new stake in shares of ANI Pharmaceuticals in the 3rd quarter valued at about $3,686,000. American Century Companies Inc. boosted its position in shares of ANI Pharmaceuticals by 99.2% in the 2nd quarter. American Century Companies Inc. now owns 99,831 shares of the specialty pharmaceutical company’s stock valued at $6,357,000 after purchasing an additional 49,717 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in ANI Pharmaceuticals by 3.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 630,226 shares of the specialty pharmaceutical company’s stock worth $40,132,000 after buying an additional 21,053 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on ANIP shares. Piper Sandler began coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 price objective for the company. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. HC Wainwright restated a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Truist Financial upped their price target on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday, October 22nd. Finally, Raymond James lifted their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research report on Wednesday, September 18th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $77.33.

ANI Pharmaceuticals Price Performance

ANIP stock opened at $56.58 on Friday. ANI Pharmaceuticals, Inc. has a 12-month low of $48.20 and a 12-month high of $70.81. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -102.87 and a beta of 0.71. The firm has a 50 day moving average of $58.40 and a 200-day moving average of $61.34. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company had revenue of $148.30 million during the quarter, compared to analysts’ expectations of $144.37 million. During the same quarter in the previous year, the business posted $1.05 earnings per share. The firm’s quarterly revenue was up 12.5% compared to the same quarter last year. As a group, equities analysts expect that ANI Pharmaceuticals, Inc. will post 3.5 EPS for the current fiscal year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.